# Semaglutide: The Deepest Trial Record on This Desk > Semaglutide: Research Overview — British Colombia Peptides — A cited literature summary of semaglutide: GLP-1 mechanism, landmark trial results in diabetes, weight, cardiovascular and kidney outcomes, and the documented safety cautions. **02 / RESEARCH PEPTIDE FUNDAMENTALS** A GLP-1 receptor agonist with FDA approval across four indications, and the outcome trials to back each one. ## The short version Semaglutide is a synthetic version of a gut hormone called GLP-1, engineered to survive in the bloodstream for about a week instead of about two minutes. It is approved by the FDA for type 2 diabetes, chronic weight management, lowering cardiovascular risk in people with existing heart disease, and, since 2025, a liver condition called MASH. It comes as a once-weekly injection or a once-daily pill. Of the five compounds on this desk, semaglutide has by far the largest human trial base: tens of thousands of participants across multiple large randomized controlled trials. In the STEP 1 trial it produced -14.9% average body-weight change versus -2.4% for placebo over 68 weeks [11]. In SELECT, in more than 17,000 people with existing cardiovascular disease, it cut major cardiac events by 20% [10]. It also lost a head-to-head weight-loss comparison against tirzepatide by roughly 6.5 percentage points [8] — a useful reminder that even an approved, well-studied drug has documented limits. ## What it is Semaglutide is a 31-amino-acid analogue of human GLP-1, sharing about 94% of the native hormone's sequence. Two changes give it its defining pharmacology: at position 8, a substitution blocks the enzyme that would normally break the hormone down within minutes; at position 26, a fatty side chain is attached that binds tightly and reversibly to albumin, the most abundant protein in blood. That albumin binding shields the peptide from clearance and is the entire structural reason once-weekly dosing works. ## How it works Semaglutide activates GLP-1 receptors throughout the body. At the pancreas, it boosts insulin release only when blood sugar is already elevated and suppresses glucagon, the hormone that raises blood sugar — a glucose-dependent mechanism that limits the risk of blood sugar dropping too low. It also slows how quickly the stomach empties, which blunts post-meal glucose spikes and is a major reason nausea is a common side effect. Its weight-loss effect is mostly centered in the brain. The peptide reaches appetite-control circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing the ones that drive hunger. Users and researchers describe this as reduced "food noise" — a quieting of the constant background thoughts about eating — rather than simple appetite loss. ## What the research shows *Weight management (STEP 1).* In 1,961 adults with overweight or obesity and no diabetes, once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% versus -2.4% with placebo at 68 weeks — a difference of roughly 12.4 percentage points [11]. *Cardiovascular outcomes (SELECT).* In 17,604 adults with existing cardiovascular disease and overweight or obesity but no diabetes, semaglutide 2.4 mg reduced the combined risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke by 20% relative to placebo (HR 0.80; P<0.001) [10]. *Kidney outcomes (FLOW).* In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg reduced major kidney-disease events by 24% versus placebo (HR 0.76) [9]. *Head-to-head against tirzepatide (SURMOUNT-5).* In 751 adults with obesity, tirzepatide produced greater weight loss than semaglutide at 72 weeks (-20.2% vs -13.7%, P<0.001) — the clearest evidence that semaglutide, despite its record, is not the strongest incretin agent available [8]. *Overall safety.* A dedicated safety review concludes semaglutide carries a favorable overall risk-benefit profile in type 2 diabetes, dominated by mild-to-moderate transient gastrointestinal effects — nausea in roughly a third of patients — plus an increased risk of gallstone-related biliary disease, with pancreatic and thyroid-cancer signals still unconfirmed due to low event counts [12]. ## Reported effects, cautions & safety *Reported effects (anecdotal, not clinical evidence):* the single most common description from patient communities is that "food noise" — the constant background chatter about the next meal — goes quiet within the first week or two, alongside sharply reduced cravings for sugar and fried food. Most reviewers report steady weight loss over months, and many with type 2 diabetes describe improved blood-sugar readings. A widely discussed secondary observation is reduced interest in alcohol. On the adverse side, nausea is the single most reported effect, mentioned by roughly a third of reviewers and occasionally escalating to vomiting, typically peaking after dose increases. A distinctive, frequently mentioned complaint is sulfur-smelling "egg burps." Bowel changes — constipation, diarrhea, or both alternating — reflux, early fatigue, and occasional headaches or dizziness round out the common list; a smaller group reports hair shedding and facial gauntness tied to the pace of weight loss rather than the drug itself. *Cited cautions from the literature:* - **Gastrointestinal intolerance, especially during dose escalation** — the dominant adverse effect and leading cause of discontinuation in trials [12]. - **Personal or family history of medullary thyroid carcinoma or MEN-2** is a contraindication, based on a rodent boxed warning; human data have not established a clear thyroid-cancer risk [12]. - **Acute pancreatitis** is a class warning; treatment is stopped if suspected, though pancreatic-cancer signals remain unconfirmed given low incidence [12]. - **Gallbladder and biliary disease** risk is increased, attributed largely to the rate and magnitude of weight loss [12]. - **Pre-existing diabetic retinopathy with rapid glycemic correction** showed a significantly higher complication rate in SUSTAIN-6 [12]. - **Loss of lean muscle mass** accompanies the fat loss in body-composition substudies, a sarcopenia concern especially for older adults [12]. - **Weight regain after stopping** — roughly 11.6 percentage points regained within a year in the STEP 1 extension, framing this as chronic rather than curative therapy [12]. - **Pregnancy is contraindicated**, with label guidance advising discontinuation roughly two months before a planned pregnancy given the peptide's week-long half-life [12]. - **Oral formulation requires strict fasted administration** — very low absorption (~0.4-1%) makes timing errors meaningful [12]. ## Where it fits in Research Peptide Fundamentals Semaglutide is the evidence anchor of this desk: the compound with FDA approval, multiple large outcome trials, and a well-characterized safety record against which the other four can be measured. It stands in sharp contrast to [BPC-157](/bpc-157) and [ipamorelin](/ipamorelin), both of which remain unapproved research chemicals with a fraction of the human data. See the full picture on the [comparison page](/compare). --- A literature desk on five research peptides, read against the Canadian regulatory backdrop — not a clinic, not a vendor, not a prescription.